ProCE Banner Activity

Imbokodo: Phase IIb Trial of Heterologous HIV-1 Vaccine Regimen Among Women in Sub-Saharan Africa at High Risk for HIV Infection

Slideset Download
Conference Coverage
Despite having a favorable safety profile, the heterologous Imbokodo HIV-1 vaccine regimen did not provide statistically significant protection against HIV-1 among younger women at high risk for HIV-1 acquisition in sub-Saharan Africa.

Released: February 17, 2022

Expiration: February 16, 2023


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck & Co., Inc.

ViiV Healthcare